180 Life Sciences Corp. has announced the approval of the Fourth Amendment to its 2022 Omnibus Incentive Plan and the new 2025 Option Incentive Plan, following stockholder approval at the recent annual meeting. The Fourth Amendment increases the number of shares available under the incentive plan by 4,000,000, bringing the total to 5,000,000 shares, with provisions for annual increases tied to the company's outstanding common stock. The 2025 Option Plan, initially approved by the board on June 17, 2025, was also sanctioned by stockholders and permits the company to grant stock options, which cannot be exercised prior to stockholder approval. These plans are in line with Nasdaq Capital Market regulations, ensuring compliance and flexibility in equity arrangements.